Natco Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1995-01-01
- Employees
- 1K
- Market Cap
- $3.2B
- Website
- http://www.natcopharma.co.in
Clinical Trials
4
Active:2
Completed:0
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
Phase 2
Active, not recruiting
- Conditions
- CarcinomaRecurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- NATCO Pharma Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT05283226
- Locations
- 🇺🇸
Providence Medical Foundation -Fullerton, Fullerton, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Lynn Cancer Center, Boca Raton, Florida, United States
News
No news found